Site for Abaloparatide versus Placebo for Pelvic Fracture Healing - A Phase 2 Randomized Controlled Trial

Go Back to All Clinical Trials

Site for Abaloparatide versus Placebo for Pelvic Fracture Healing - A Phase 2 Randomized Controlled Trial

Brief description of study

Site for This is a prospective randomized, double-blinded, placebo-controlled, phase 2, three-month study of the efficacy of abaloparatide in postmenopausal women and men = 50 years of age with acute fractures of the pelvis. We will extend this study with 9 months of open label abaloparatide to determine if any potential differences between the placebo and abaloparatide groups during the 3 months of treatment are evident and persist over time, even in patients who use abaloparatide after the three-month placebo controlled intervention. Our primary outcome is CT evidence of fracture healing at the 12-week endpoint. After initiating ABALOPARATIDE or ABALOPARATIDE placebo, all patients will get follow-up pelvic radiographs following standard care and radiographs will stop when healing occurs.

Clinical Study Identifier: s20-00894

ClinicalTrials.gov Identifier: NCT04249232

Principal Investigator: Kenneth A Egol.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies